Navigation Links
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
Date:7/5/2011

AMSTERDAM, July 6, 2011 /PRNewswire/ --


 

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

"We are very fortunate to have attracted Carlos to AMT. He has joined the company at a pivotal point as we continue to pursue the approval our lead gene therapy Glybera with the EMA," stated Jörn Aldag, CEO of AMT. "His expertise in product development and related interaction with global regulatory bodies in the orphan drug field will prove invaluable, not only with Glybera, but also as we advance development of our gene therapy pipeline."

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held the position of Medical Director for over 5 years. During his tenure, he oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing authorisation renewals for two products, three orphan drug designations and development of pediatric investigation plans. He was also responsible for the clinical development in the pediatric field of orphan drugs in therapeutic areas of metabolic disorders, immunology, dermatology, cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Basel, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities. From 2001-2005, he was managing director of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programs for pharmaceutical and healthcare products.
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
9. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
10. NIH grant ratchets up ASU research in molecular motors
11. SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... e2b teknologies , a premier Sage ... Ohio, today announced a leading independent multi-specialty physician group ... to the latest version of Sage 100 ERP ... its kind in the region, the organization has an ... efficiency and data accessibility are paramount to their ongoing ...
(Date:3/4/2015)... March 4, 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... for the: , 3.75% Convertible Senior Notes due ... common stock per $1,000 principal amount or approximately $5.72 per ... for the note is adjusted in connection with the regular ... to all stockholders who own shares of PDL on March 5, ...
(Date:3/4/2015)... BROOKLYN, N.Y. , March 4, 2015  Brooklyn ... treat their acute and chronic pain and injuries. ... to announce the grand opening of his NJS Physical ... NY on Thursday, March 5, 2015. Health ... the facility, which is located at 1178 Flatbush Avenue. ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of the "Global Biologics and ... offering. , The Global Biologics ... and in-depth study on the current state of ... report provides a basic overview of the industry ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biologics and Biosimilars Industry Report 2015-2020 2
... ... Simplify Clinical Workflow Using iSirona Technology , ... Panama City, Fla. (PRWEB) November 18, 2009 ... the successful "go-live" of iSirona,s DeviceConX at University Hospitals Geneva Medical Center and ...
... Then it was the cylindrically shaped nanotubes. Now, the ... a remarkably flat molecule made of carbon atoms ... Not only is this the thinnest material ... steel and it conducts electricity better than any other ...
... , HAIKOU ... Pharma") (NYSE Amex: CPHI ), which develops,manufactures, and markets ... at the Brean Murray, Carret & Co. 2009 China,Growth Conference, ... in New York. Management is scheduled to present at ...
Cached Biology Technology:iSirona Announces Go-live at University Hospitals in Cleveland 2iSirona Announces Go-live at University Hospitals in Cleveland 3New study confirms exotic electric properties of graphene 2New study confirms exotic electric properties of graphene 3China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference 2
(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... Ph.D., Assistant Professor, Department of Microbiology & Immunology, University ... honored with one of two 2012 Merck Irving S. ... young scientists to recognize and award excellence in basic ... in memory of Irving S. Sigal, an instrumental figure ...
... known as vampire spiders, are picky eaters by any standards. ... Nelson from the University of Canterbury, New Zealand, says, ,You ... the field that there is a high number of mosquitoes ... diet further, he found that the spiders were even more ...
... Cold Spring Harbor, NY A rose by any other ... scientists interested in understanding the chemical components of its fragrance ... That,s because in biology, an organism,s scientific (taxonomic) name ... data on the genetic, ecological, and agricultural particulars of ...
Cached Biology News:The American Society for Microbiology honors Susan Sharp 2Vampire jumping spiders identify victims by their antennae 2Vampire jumping spiders identify victims by their antennae 3New release of Web-based resource resolves confusion over plant names 2New release of Web-based resource resolves confusion over plant names 3